Carbohydrate Deficient Glycoprotein Syndrome Type Ip

Carbohydrate-deficient glycoprotein syndrome type Ip is a very rare, inherited metabolic disease. It affects how the body attaches sugar chains to proteins—a process called N-linked glycosylation. In ALG11-CDG, there are harmful changes (variants) in a gene called ALG11. This gene makes an enzyme (a mannosyltransferase) that adds two mannose sugars during the early steps of building a special “starter” sugar on a lipid carrier inside the endoplasmic reticulum of cells. When ALG11 does not work well, many proteins are not glycosylated correctly. That can disturb the function of many organs, especially the brain, muscles, eyes, and the gastrointestinal system. The condition is autosomal recessive, meaning a child is affected when they inherit one non-working copy of the gene from each parent. CDG Hub+1

ALG11-CDG (formerly CDG type Ip) is a very rare, inherited condition that affects how the body adds sugar chains to many proteins. This “sugar-adding” step is called N-glycosylation. It happens in a cell compartment called the endoplasmic reticulum (ER). In ALG11-CDG, a gene named ALG11 does not work properly. The ALG11 gene normally makes an enzyme (a worker protein) called a mannosyltransferase. This enzyme’s job is to attach the 4th and 5th mannose sugars to a growing “starter sugar chain,” called a lipid-linked oligosaccharide (LLO). When ALG11 is defective, the chain is left incomplete. As a result, many body proteins do not receive full sugar chains, so they cannot fold, move, or function normally. This leads to problems in the brain, eyes, gut, muscles, and other organs, usually beginning in infancy. There is no approved disease-specific medicine yet; treatment focuses on managing symptoms and preventing complications. CDG Hub

Children with ALG11-CDG can have low muscle tone (hypotonia), developmental delays, seizures, feeding problems, and a small head size (microcephaly). Some babies become very sick early in life. Others live longer but have learning and movement difficulties. The range is wide—that is, the disease has a spectrum from severe infantile forms to milder presentations. NCBI+1

---

Other names

• ALG11-CDG

• CDG-Ip or CDG type Ip

• Carbohydrate-deficient glycoprotein syndrome type Ip

• CDG1P

• Asparagine-linked glycosylation 11 deficiency
  These names all refer to the same disorder caused by disease-causing variants in ALG11 on chromosome 13q14.3. Orpha.net+1

---

Types

There is only one genetic type—pathogenic variants in ALG11—but doctors often talk about clinical patterns within ALG11-CDG:

1. Severe early-infantile encephalopathic form. Babies present within the first months with profound hypotonia, intractable seizures (sometimes with a burst-suppression EEG pattern), feeding difficulty, failure to thrive, and microcephaly. Some infants have gastrointestinal bleeding and may not survive early childhood. Default+1

2. Childhood-onset neurodevelopmental form. Children show global developmental delay, hypotonia, strabismus, seizures that may be better controlled, and stable but persistent microcephaly. Sensorineural hearing loss can occur. Brain MRI may show cerebellar or cerebral atrophy or delayed myelination. Orpha.net+1

3. Broader multisystem involvement. Some individuals show additional features such as distinctive facial gestalt, temperature instability, inverted nipples or fatty pads, and coagulation abnormalities—features that occur in several type-I CDGs. GARD Information Center

These “types” are clinical descriptions, not separate genetic diseases. All result from ALG11 dysfunction within the Type-I CDG group (defects in building the lipid-linked oligosaccharide before transfer to proteins). Wikipedia

---

Causes

Important: The root cause is the same in every patient—two disease-causing variants in the ALG11 gene. Below are 20 mechanism-level causes and contributors that explain how and why the disease appears or varies in severity.

1. Biallelic ALG11 pathogenic variants. Both copies of ALG11 carry harmful changes (missense, nonsense, frameshift, splice). This is the fundamental cause. CDG Hub

2. Loss of ALG11 enzyme function. The mannosyltransferase cannot add the 4th and 5th mannose residues during lipid-linked oligosaccharide (LLO) synthesis. CDG Hub

3. Defective LLO assembly (Type-I CDG mechanism). When early LLO steps fail, many proteins receive too few glycans. Wikipedia

4. Reduced glycoprotein stability. Unglycosylated proteins may misfold or be degraded faster, lowering levels of key proteins in brain, liver, and muscle. NCBI

5. Neuronal network dysfunction. Under-glycosylation disturbs ion channels and synaptic proteins, raising seizure risk. NCBI

6. Myelination impairment. Proper myelin formation needs glycoproteins; disruption can contribute to delayed myelination seen on MRI. NCBI

7. Disordered cell-cell signaling. Many receptors require N-glycans; signaling in growth and development is affected. NCBI

8. Muscle hypotonia from glycoprotein deficits. Structural and signaling proteins at the neuromuscular junction can be hypoglycosylated. NCBI

9. Brain growth restriction (microcephaly). Abnormal glycosylation interferes with neurogenesis and brain growth. Orpha.net

10. Coagulation pathway imbalance. Several clotting factors are glycoproteins; under-glycosylation can alter levels and activity. NCBI

11. Gastrointestinal mucosal fragility. Glycoproteins protect gut lining; defects can contribute to vomiting or bleeding. GARD Information Center

12. Autonomic dysregulation (temperature swings). Glycosylation supports autonomic receptors; instability may cause temperature fluctuations. GARD Information Center

13. Hearing pathway involvement. Sensorineural hearing loss likely reflects under-glycosylation in inner ear or auditory pathways. ScienceDirect

14. Immune system imbalance. Some immune proteins are glycosylated; recurrent infections or inflammatory changes may reflect this. NCBI

15. Energy and feeding difficulty. Poor glycosylation can impair GI motility and swallowing coordination, worsening nutrition. GARD Information Center

16. Variant class effect. Missense variants that reduce activity may give milder disease than truncating variants that abolish activity. (General genotype-phenotype principle in CDG-I.) NCBI

17. Compound heterozygosity patterns. Different variants on the two alleles can mix severe and mild effects. CDG Hub

18. Modifier genes. Other glycosylation or dolichol-pathway genes may modify severity across CDG-I disorders. Wikipedia

19. Environmental stressors. Intercurrent illness, fever, and poor nutrition can unmask or worsen symptoms in infants with CDG-I. NCBI

20. Diagnostic delay. Late recognition means delayed supportive care, allowing complications (e.g., malnutrition, seizures) to worsen outcomes. NCBI

---

Common symptoms and signs

1. Global developmental delay. Children reach milestones (head control, sitting, walking, speech) later than expected because the brain’s glycoprotein-dependent networks do not develop normally. NCBI

2. Hypotonia (low muscle tone). Babies feel “floppy” because muscles and neuromuscular signaling rely on well-glycosylated proteins. GARD Information Center

3. Seizures. Many patients develop early and sometimes hard-to-control seizures; EEG can show severe patterns such as burst-suppression in the sickest infants. Default

4. Microcephaly (small head). Ongoing brain growth is limited; head circumference tracks below normal curves. Orpha.net

5. Feeding difficulty and failure to thrive. Poor suck, reflux, vomiting, and low weight gain are common and may require feeding tube support. GARD Information Center

6. Gastrointestinal bleeding or persistent vomiting (some cases). The gut lining is vulnerable, and severe illness may occur in infancy. NCBI

7. Strabismus and ocular motor problems. Misalignment of the eyes is frequent in CDG-I conditions, including ALG11-CDG. NCBI

8. Sensorineural hearing loss (some patients). Hearing tests may show inner-ear or nerve involvement. ScienceDirect

9. Distinctive facial features. A high forehead, low posterior hairline, and other subtle features may be noted. GARD Information Center

10. Temperature instability. Babies may have unusual swings in body temperature due to autonomic dysfunction. GARD Information Center

11. Coagulation abnormalities. Easy bruising or abnormal labs may appear because clotting proteins are glycosylated. NCBI

12. Growth restriction. Weight and length may track low, reflecting feeding issues and systemic illness. GARD Information Center

13. Movement or coordination problems. Ataxia or poor coordination can result from cerebellar involvement or hypotonia. NCBI

14. Behavioral or learning challenges. As children grow, intellectual disability or learning disorders are common. Orpha.net

15. Respiratory vulnerability. Weak tone and swallowing discoordination raise aspiration and infection risk in infants. (General CDG-I complication noted across types.) NCBI

---

Diagnostic tests

A) Physical examination (bedside assessment)

1. General growth and nutrition check. Weight, length, and head size are tracked; low growth or microcephaly supports suspicion. GARD Information Center

2. Neurologic tone and reflex exam. Low tone, weak reflexes, or abnormal posturing raise concern for a congenital glycosylation defect. NCBI

3. Dysmorphology assessment. A clinical geneticist looks for subtle facial signs (e.g., high forehead, low posterior hairline) that fit ALG11-CDG. GARD Information Center

4. Ophthalmic screening in clinic. Strabismus, limited tracking, or nystagmus can be recognized on exam and prompt formal eye testing. NCBI

5. Cardiorespiratory and abdominal exam. Checks for murmurs, hepatosplenomegaly, or signs of aspiration—findings that guide supportive care in CDG-I disorders. NCBI

B) Manual / bedside functional tests

6. Feeding/swallow evaluation at bedside. Simple test feeds and observation of suck–swallow–breathe coordination identify aspiration risk and need for therapy. NCBI

7. Developmental screening tools (e.g., Denver-style checklists). Structured play-based tasks quantify motor and language delays. NCBI

8. Cover–uncover eye test. A quick manual screen for strabismus that guides referral to pediatric ophthalmology. NCBI

9. Bedside hearing checks. Simple response-to-sound tests can suggest hearing issues and trigger formal audiology testing. ScienceDirect

10. Temperature monitoring diaries. Repeated measurements document instability that is common in some CDG-I infants. GARD Information Center

C) Laboratory and pathological tests

11. Transferrin glycosylation analysis (screening test). Isoelectric focusing or mass spectrometry of serum transferrin shows a Type-I pattern, the hallmark of defects in early LLO assembly (including ALG11-CDG). This is a key screening step. Wikipedia

12. Serum N-glycan profiling. Broader mass-spectrometry glycan studies confirm under-glycosylation and help separate Type-I from other patterns. Wikipedia

13. Coagulation panel (PT/INR, aPTT) and specific factors. Abnormal results support glycosylation-related coagulopathy common in CDG-I. NCBI

14. Liver function tests and albumin. Transaminase elevations or low albumin may reflect hepatic involvement and poor nutrition. NCBI

15. Molecular genetic testing of ALG11. A CDG gene panel or exome/genome sequencing identifies biallelic pathogenic variants and confirms the diagnosis. Parental testing helps interpret variant phase. CDG Hub

D) Electrodiagnostic tests

16. EEG (electroencephalography). Captures seizure activity; in severe infantile cases, a burst-suppression pattern may appear and can influence treatment choices. Default

17. Brainstem auditory evoked responses (BAER/ABR). Objective test for sensorineural hearing loss when routine audiology is difficult in infants. ScienceDirect

18. Nerve conduction studies / EMG (selected cases). Assess peripheral neuropathy or neuromuscular junction involvement when weakness is out of proportion. NCBI

E) Imaging tests

19. Brain MRI. May show cerebral or cerebellar atrophy or delayed myelination, which supports a congenital glycosylation disorder and helps with prognosis. Orpha.net

20. Abdominal ultrasound (as indicated). Screens for organomegaly or other complications when liver involvement or GI bleeding is suspected. NCBI

Non-pharmacological treatments

There is no approved disease-specific therapy for ALG11-CDG today; care is supportive and proactive. The items below are practical, family-centered strategies used to improve function, comfort, and safety. CDG Hub

1. Early intervention therapy
   Purpose: Boost developmental skills from infancy.
   Mechanism: High-frequency, play-based stimulation strengthens brain circuits despite glycoprotein defects.

2. Physiotherapy (gross motor)
   Purpose: Improve tone, posture, head control, sitting/standing.
   Mechanism: Repetition drives motor learning and counters hypotonia/hypertonia patterns.

3. Occupational therapy (fine motor & daily living)
   Purpose: Improve hand skills, feeding tools use, dressing, daily routines.
   Mechanism: Task-specific practice builds adaptive pathways.

4. Speech-language therapy (communication)
   Purpose: Support speech, language, AAC devices if needed.
   Mechanism: Structured language input and assistive tech bypass motor/processing limits.

5. Feeding therapy
   Purpose: Safer swallowing, reduce aspiration, improve nutrition.
   Mechanism: Positioning, pacing, texture changes, and oral-motor exercises.

6. Nutrition planning with a dietitian
   Purpose: Prevent malnutrition; optimize calories, protein, micronutrients.
   Mechanism: Tailored meal plans, calorie-dense formulas, reflux-friendly strategies.

7. Reflux management (non-drug)
   Purpose: Reduce vomiting and discomfort.
   Mechanism: Smaller frequent feeds, upright positioning after feeds, thickened feeds as advised.

8. Vision therapy & low-vision supports
   Purpose: Maximize visual input and tracking.
   Mechanism: Environmental contrast, lighting, and exercises to strengthen pathways.

9. Hearing supports
   Purpose: Ensure consistent access to sound/language.
   Mechanism: Early amplification (when indicated), environmental sound optimization.

10. Seizure first-aid education for caregivers
    Purpose: Safety during events; reduce injury.
    Mechanism: Clear rescue plan, positioning, timing, emergency thresholds.

11. Sleep hygiene program
    Purpose: Improve sleep quality, which helps seizures and development.
    Mechanism: Consistent routines, dark/quiet environment, timing of naps/feeds.

12. Temperature regulation strategies
    Purpose: Manage occasional temperature instability.
    Mechanism: Layered clothing, environmental control, hydration.

13. Postural management / orthoses
    Purpose: Prevent contractures/scoliosis; improve sitting tolerance.
    Mechanism: Seating systems, standers, ankle-foot orthoses.

14. Behavioral therapy
    Purpose: Support attention, transitions, and coping.
    Mechanism: Positive reinforcement, structured schedules.

15. Care coordination / palliative care
    Purpose: Align care with family goals; improve comfort and quality of life.
    Mechanism: Symptom control, anticipatory guidance, psychosocial support.

16. Infection-prevention habits
    Purpose: Reduce illness that can worsen feeding and seizures.
    Mechanism: Vaccines (per schedule), hand hygiene, exposure reduction. (General CDG care.) BioMed Central

17. Education plans (IEP/IFSP)
    Purpose: Access to school accommodations and therapies.
    Mechanism: Legal supports for specialized instruction.

18. Hydration planning
    Purpose: Avoid dehydration from vomiting/illness.
    Mechanism: Oral rehydration, scheduled fluids, enteral support.

19. Family genetic counseling
    Purpose: Understand inheritance and future options.
    Mechanism: Risk calculation, carrier testing, PGT/PND discussion. CDG Hub

20. Clinical trial awareness
    Purpose: Learn about natural-history or future interventional studies.
    Mechanism: Connect with FCDGC natural history study (NCT04199000). CDG Hub

---

Drug treatments

Important: There is no proven, disease-specific medication for ALG11-CDG at this time. Medicines are used to treat symptoms (such as seizures, reflux, spasticity) following standard pediatric protocols and specialist guidance. Exact dosing must be individualized by the child’s clinicians—especially because many children have feeding issues and complex needs. CDG Hub

Below are common classes with examples, purposes, and basic mechanisms:

1. Antiseizure medicines (ASMs): levetiracetam, valproate, clobazam, topiramate, oxcarbazepine, vigabatrin (choice depends on seizure type).
   Purpose: Control epilepsy. Mechanism: Stabilize neuronal firing via GABA enhancement, sodium-channel modulation, or SV2A binding. (Epilepsy is frequent in ALG11-CDG.) CDG Hub

2. Rescue seizure meds: intranasal midazolam or diazepam for prolonged seizures per emergency plan.
   Purpose: Stop clusters/status early. Mechanism: Rapid GABA-A activation. General pediatric epilepsy practice.

3. Ketogenic diet (medical nutrition therapy, may be adjunct to meds)
   Purpose: Reduce seizures in refractory epilepsy. Mechanism: Ketone bodies alter neuronal excitability. (Use under neurology/dietitian supervision.)

4. Anti-reflux drugs: proton pump inhibitors (e.g., omeprazole), H2 blockers (e.g., ranitidine alternatives depending on local guidance).
   Purpose: Reduce acid injury and vomiting. Mechanism: Lower gastric acid output. (Used symptomatically.)

5. Pro-kinetics (specialist-directed): e.g., erythromycin low-dose.
   Purpose: Improve gastric emptying in severe reflux/gastroparesis. Mechanism: Motilin receptor agonism.

6. Antiemetics (e.g., ondansetron short-term).
   Purpose: Control vomiting episodes. Mechanism: 5-HT3 receptor blockade.

7. Spasticity/tone agents: baclofen or tizanidine when hypertonia limits comfort/function.
   Purpose: Reduce painful spasms. Mechanism: GABA-B agonism / alpha-2 agonism.

8. Sleep aids (behavioral first): melatonin under pediatric guidance.
   Purpose: Improve sleep; better seizure control and daytime function. Mechanism: Circadian entrainment.

9. Constipation management: polyethylene glycol (PEG).
   Purpose: Prevent discomfort, improve feeding. Mechanism: Osmotic stool softening.

10. Analgesics/antipyretics: acetaminophen as needed.
    Purpose: Comfort during illnesses; fever control. Mechanism: Central COX modulation.

11. Bronchodilators if reactive airways are present (case-by-case).
    Purpose: Ease breathing during infections. Mechanism: Beta-2 agonism.

12. Antibiotics when infections are diagnosed (not routine).
    Purpose: Treat bacterial illness that can destabilize feeding or seizures. Mechanism: Pathogen-specific.

13. Vitamin D with calcium (if deficient).
    Purpose: Bone health with limited mobility/feeding issues. Mechanism: Support mineralization.

14. Iron supplementation (if iron-deficiency anemia is present).
    Purpose: Improve energy and development. Mechanism: Replete iron stores.

15. Multivitamin/mineral (dietitian-guided).
    Purpose: Cover gaps from restricted intake. Mechanism: Replace missing micronutrients.

16. Laxative “rescue” options (short-term, as advised).
    Purpose: Break constipation cycles. Mechanism: Stimulant/osmotic effects.

17. Antispasmodics for GI cramping (specialist-guided).
    Purpose: Reduce discomfort. Mechanism: Smooth-muscle relaxation.

18. Anticholinergics for drooling (selected cases).
    Purpose: Reduce aspiration risk and skin irritation. Mechanism: Lower salivary secretion.

19. Topical treatments for skin breakdown
    Purpose: Protect skin in drooling/feeding tube sites. Mechanism: Barrier repair.

20. Vaccinations (not a “drug for ALG11-CDG,” but critical).
    Purpose: Prevent infections that worsen overall status. Mechanism: Immune priming per schedules. (General CDG care.) BioMed Central

Note: Disease-modifying sugars (like mannose for MPI-CDG or galactose for PGM1-CDG) do not have evidence for ALG11-CDG today. Research is ongoing. CDG Hub

Dietary molecular supplements

Always coordinate with your child’s clinicians and dietitian.

1. High-calorie formula or modulars (MCTs, carbohydrate modules) to meet energy needs when intake is low.

2. Protein optimization to support growth and tissue repair.

3. Omega-3 (DHA/EPA) for general neurodevelopmental support (adjunctive, not disease-specific).

4. Multivitamin with trace elements to prevent deficits.

5. Vitamin D (monitor levels).

6. Calcium if dietary intake is low.

7. Iron if deficient (lab-guided).

8. Zinc if poor growth and low levels.

9. Sodium/potassium repletion during vomiting/illness (medical guidance).

10. Fiber or PEG support to prevent constipation that worsens feeding.

(These are supportive nutrition choices, not proven to fix glycosylation in ALG11-CDG.) CDG Hub+1

---

Immunity-booster / regenerative / stem-cell” drugs—

• There are no validated immune-booster, regenerative, or stem-cell drugs for ALG11-CDG today.

• Experimental directions (conceptual, not clinic-ready):

  1. Gene replacement/editing research (theory for monogenic diseases; not an active therapy for ALG11 yet).

  2. Pharmacologic chaperones to stabilize partially active ALG11 variants (hypothetical).

  3. ER-stress modulators to help cells handle misfolded proteins (preclinical concept).

  4. Substrate balancing in glycosylation (works for some other CDGs; no evidence in ALG11).

  5. mRNA therapy concepts (very early stage for rare enzymes).

  6. Cell-based approaches (not appropriate/established for this pathway).
     Bottom line: Do not use unproven “immune booster” products. Focus on vaccinations, nutrition, sleep, and infection prevention. Track clinical trials and registries via FCDGC. CDG Hub

---

Surgeries/procedures

1. Gastrostomy tube (G-tube)
   Why: When oral feeding is unsafe or insufficient. Benefit: Reliable nutrition, lower aspiration risk.

2. Fundoplication (select cases)
   Why: Severe reflux causing pain, aspiration, or bleeding despite maximal medical care. Benefit: Mechanical reflux control.

3. Strabismus surgery
   Why: Persistent eye misalignment affecting vision development. Benefit: Better alignment and potential visual development.

4. Orthopedic procedures (e.g., tendon releases)
   Why: Fixed contractures or scoliosis impairing care/comfort. Benefit: Comfort, positioning, hygiene.

5. Vagus nerve stimulator (VNS)
   Why: Refractory epilepsy when multiple ASMs fail. Benefit: Reduce seizure frequency/intensity in some patients.

(All are individualized decisions by a multidisciplinary team.)

---

Preventions

1. Routine vaccines (family and child).

2. Hand hygiene and illness avoidance during peaks.

3. Seizure safety plan and caregiver training.

4. Nutrition and hydration plans to prevent decompensation.

5. Aspiration prevention (positioning, swallow strategies).

6. Skin care to prevent breakdown (especially around tubes).

7. Sleep routine to stabilize seizures/behavior.

8. Regular dental care (reflux can erode enamel).

9. Physical therapy home program to prevent contractures.

10. Regular specialist follow-up (neurology, GI, ophthalmology, genetics).

---

When to see doctors urgently

• New or worsening seizures, long seizures, or clusters.

• Signs of dehydration (less urine, lethargy) from vomiting/illness.

• Breathing problems or suspected aspiration.

• Blood in vomit or stool, or repeated gastric bleeding.

• Rapid regression in skills or sudden weakness.

• Fever with poor intake that you cannot manage at home.

(For non-urgent concerns—feeding, sleep, therapy needs—arrange routine follow-up.)

---

What to eat and what to avoid

• Eat: Energy-dense, nutrient-rich foods your child can safely handle (dietitian-guided). Use thickened liquids or soft textures if swallowing is an issue. Offer small, frequent meals and allow extra time to feed.

• Avoid: Foods that trigger reflux (very acidic, spicy, large fatty meals right before sleep) and unsafe textures that increase choking risk. If a gastrostomy tube is present, follow formula and flush instructions exactly. (All individualized by the care team.)

---

FAQs

1. Is ALG11-CDG the same as CDG-Ip?
   Yes. CDG-Ip is the older name; today we use ALG11-CDG. CDG Hub

2. How common is it?
   Extremely rare—only a small number of patients have been reported in the medical literature. CDG Hub

3. What causes it?
   Pathogenic variants in both copies of ALG11 (autosomal recessive). CDG Hub

4. Which body systems are affected?
   Often the brain (development, seizures), eyes, muscles, feeding/gut, and sometimes hearing. CDG Hub

5. How is screening done?
   A transferrin test showing a Type I pattern suggests a CDG; genetic testing confirms ALG11-CDG. CDG Hub

6. Is there a cure or approved medicine?
   No disease-specific therapy yet; care is supportive and symptom-focused. CDG Hub

7. Do special sugars help, like in some other CDGs?
   Not for ALG11-CDG based on current evidence. CDG Hub

8. What about life expectancy?
   It varies by severity; reported cases range from early infancy to adolescence. CDG Hub

9. Can it be prevented?
   You cannot change the child’s genetics, but genetic counseling can help with future pregnancy planning. CDG Hub

10. Is it inherited from parents who look healthy?
    Yes. Parents are typically healthy carriers. CDG Hub

11. Is eye surgery ever needed?
    Sometimes, for significant strabismus to support visual development.

12. Why is feeding so hard?
    Low tone, reflux, and coordination issues are common. Therapy and nutrition help. CDG Hub

13. Are there research studies?
    Yes—natural-history studies are active through the rare-disease network (FCDGC). CDG Hub

14. Will my child walk or talk?
    Abilities vary. Early, intensive therapies maximize each child’s potential.

15. Where can families learn more?
    Trusted resources include CDG Hub, Orphanet, and NORD/GARD summaries. CDG Hub+2Orpha.net+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 12, 2025.